Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?

scientific article published on September 2011

Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years? is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S12032-010-9516-1
P698PubMed publication ID20390469

P2093author name stringFaysal Dane
Gul Basaran
Selcuk Seber
Taner Korkmaz
Handan Kaya
Ferhat Telli
Bahadir Gulluoglu
Hale B Caglar
Cabuk Devrim
Fulden P Yumuk
Muharrem Kocak
Serdar N Turhal
P2860cites workTaxanes for adjuvant treatment of early breast cancerQ24242987
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsQ27860709
Gene expression profiling predicts clinical outcome of breast cancerQ27860732
A gene-expression signature as a predictor of survival in breast cancerQ27860945
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsQ29547513
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involveQ31826117
Revision of the American Joint Committee on Cancer staging system for breast cancerQ38432706
Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodesQ40943517
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancerQ42163501
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifenQ43233449
Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer GroupQ43251299
Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF.Q43621488
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trialQ44865908
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvementQ44968669
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer casesQ45212226
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NQ46378871
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trialsQ46828225
HER-2 as a target for breast cancer therapy.Q51766984
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and LeuQ57578575
Benefit of taxanes as adjuvant chemotherapy for early breast cancerQ61899631
Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapyQ67720581
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancerQ70736024
Management and survival of female breast cancer: results of a national survey by the American College of SurgeonsQ71235390
The natural history of breast cancer with more than 10 positive nodesQ72289481
Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year resultsQ73443102
The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodesQ73665822
The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodesQ73932600
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomyQ74545924
P433issue3
P921main subjectlymph nodeQ170758
P304page(s)726-732
P577publication date2011-09-01
P1433published inMedical OncologyQ2152666
P1476titleClinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?
P478volume28

Reverse relations

cites work (P2860)
Q83498856Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes
Q37056926Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes
Q33636187Metastatic axillary node ratio predicts recurrence and poor long-term prognosis in patients with advanced stage IIIC (pN3) breast cancer
Q44537135Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes
Q35050980Prognostic Factors in Operated Stage IIIC, Pathological N3a Breast Cancer Patients
Q37056923Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer
Q33759691The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells

Search more.